Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States

Clinical and Diagnostic Laboratory Immunology

Volumn 11, Issue 2, 2004, Pages 351-357

  Nwanegbo, Edward ^a   Vardas, Eftyhia ^c   Gao, Wentao ^a   Whittle, Hilton ^d   Sun, Huijie ^a   Rowe, David ^b   Robbins, Paul D ^a   Gambotto, Andrea ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; NEUTRALIZING ANTIBODY; YELLOW FLUORESCENT PROTEIN;

ADENOVIRUS; ADENOVIRUS 35; ADENOVIRUS 5; ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GAMBIA; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENCE; MUCOSAL IMMUNITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RECOMBINANT GENE; SEROTYPE; SOUTH AFRICA; UNITED STATES;

ADENOVIRIDAE; ADENOVIRUS INFECTIONS, HUMAN; ADULT; ANTIBODIES, VIRAL; FLOW CYTOMETRY; GAMBIA; HUMANS; MICROSCOPY, FLUORESCENCE; NEUTRALIZATION TESTS; SEROEPIDEMIOLOGIC STUDIES; SOUTH AFRICA; UNITED STATES;

EID: 1642264887     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.11.2.351-357.2004     Document Type: Article

References (37)

1. Armentano, D., J. Zabner, C. Sacks, C. C. Sookdeo, M. P. Smith, J. A. St. George, S. C. Wadsworth, A. E. Smith, and R. J. Gregory. 1997. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71:2408-2416.
2. Brody, S. L., M. Metzger, C. Danel, M. A. Rosenfeld, and R. G. Crystal. 1994. Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum. Gene Ther. 5:821-836.
3. Chen, Y., D.-C. Yu, D. Charlton, and D. R. Henderson. 2000. Pre-existing adenovirus antibody inhibits systemic toxicity and anti-tumour activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposal for human therapy. Hum. Gene Ther. 11:1553-1567.
4. Cichon, G., H. H. Boeckh-Herwig Schmidt, E. Wehnes, T. Muller, P. Pring-Akerblom, and R. Burger. 2001. Complement activation by recombinant adenoviruses. Gene Ther. 8:1794-1800.
5. De Jong, J. C., A. G. Wermenbol, M. W. Verweij-Uijterwaal, K. V. Slaterus, G. J. van Doornum, S. H. Khoo, and J. C. Hierholzer. 1999. Adenovirus from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J. Clin. Microbiol. 37:3940-3945.
6. Fatz, W., and R. Wigand. 1985. Infection rate with adenovirus 1 to 39 in infants and adults. Immun. Infekt. 13:108-112.
7. Flomemberg, P., V. Piaskowski, R. L. Truitt, and J. T. Casper. 1995. Characterization of human proliferative T cell responses to adenovirus. J. Infect. Dis. 171:1090-1096.
8. Flomemberg, P. R., M. Chen, G. Munk, and M. S. Horwitz. 1987. Molecular epidemiology of adenoviral type 35 infections in immunocompromised hosts. J. Infect. Dis. 155:1127-1134.
9. Foy, H. M., and J. T. Grayston. 1976. Adenoviruses, p. 53-69. In A. S. Evans (ed.), Viral infections of humans: epidemiology and control. Plenum, New York, N.Y.
10. Gahery-Segard, H., V. Molinnier-Frankel, C. Leboulaire, P. Saulinier, P. Opolon, R. Lengagne, E. Gautier, A. Lecesne, L. Zitvogel, A. Venet, C. Schatz, M. Courtney, T. Lechevalier, T. Tursz, J.-G. Guillet, and F. Farace. 1997. Phase 1 trial of recombinant adenovirus gene transfer in lung cancer: longitudinal study of the immune responses to transgene and viral products. J. Clin. Investig. 100:2218-2226.
11. Gao, W., P. D. Robbins, and A. Gambotto. 2003. Human adenovirus type 35: nucleotide sequence and vector development. Gene Ther. 10:1941-1949.
12. Gilgenkrantz, H., D. Duboc, V. Julliard, D. Couton, A. Pavirani, J. G. Guilet, P. Briand, and A. Kahn. 1995. Transient expression of genes transferred in vivo into heart using first generation adenoviral vectors: role of the immune response. Hum. Gene Ther. 6:1265-1274.
13. Goossens, P. H., R. Vogels, E. Piteterman, M. J. Havenga, A. Bout, F. C. Breedveld, D. Valerio, and T. W. Huizinga. 2001. The influence of synovial fluid on adenovirus-mediated gene transfer to the synovial tissue. Arthritis Rheum. 44:48-52.
14. Hardy, S., M. Kitamura, T. Harris-Stansil, Y. Dai, and M. L. Phipps. 1997. Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71:1842-1849.
15. Hitt, M. M., and J. Gauldie. 2000. Gene vectors for cytokine expression in vivo. Curr. Pharm. Design 6:613-632.
16. Huang, S., T. Kamata, Y. Takada, Z. M. Ruggeri, and G. R. Nemerow. 1996. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J. Virol. 70:4502-4508.
17. Ilan, Y., G. Droguett, N. Roy Chowdury, Y. Li, K. Sengupta, N. R. Thummala, A. Davidson, J. Roy Chowdury, and M. S. Horwitz. 1997. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc. Natl. Acad. Sci. USA 94:2587-2592.
18. Jooss, K., L. A. Turka, and J. M. Wilson. 1998. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther. 5:309-319.
19. Kaplan, J. M., J. A. St. George, S. E. Pennington, L. D. Keyes, R. P. Johnson, S. C. Wadsworth, and A. E. Smith. 1996. Humoral and cellular immune responses of non-human primates to long term repeated lung exposure to Ad2/CFTR-2. Gene Ther. 3:117-1127.
20. Kass-Eisler, A., L. Leinwand, J. Gall, B. Bloom, and E. Falck-Pedersen. 1996. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther. 3:154-162.
21. Kay, M. A., D. Liu, and P. M. Hoogerbugge. 1997. Gene therapy. Proc. Natl. Acad. Sci. USA 94:12744-12746.
22. Kozarsky, K., and J. M. Wilson. 1993. Gene therapy: adenovirus vectors. Curr. Opin. Genet. Dev. 3:499-503.
23. Mack, C. A., W. R. Song, H. Carpenter, T. J. Wickham, I. Kovesdi, B. G. Harvey, C. J. Magovern, O. W. Isom, T. Rosengart, E. Falck-Pedersen, N. R. Hackett, R. G. Crystal, and A. Mastrangeli. 1997. Circumvection of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum. Gene Ther. 8:99-109.
24. Marshall, E. 1999. Gene therapy death prompts review of adenovirus vector. Science 286:2244-2245.
25. Mei, Y.-F., K. Lindman, and G. Wadel. 2002. Human adenoviruses of subgenera B, C and E with various tropisms differ in both binding to and replication in the epithelial A549 and 293 cells. Virology 295:30-43.
26. Molnar-Kimber, K. L., D. H. Sterman, M. Chang, E. H. Kang, M. ElBash, M. Lannuti, A. Elshami, K. Gelfand, J. M. Wilson, L. R. Kaiser, and S. M. Albelda. 1998. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy; phase 1 clinical trial for localized mesothelioma. Hum. Gene Ther. 9:2121-2133.
27. Pickles, R. J., D. McCarthy, H. Matsui, P. J. Hart, S. Randell, and R. Boucher. 1998. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J. Virol. 72:6014-6023.
28. Schnell, M. J. 2001. Viral vectors as potential HIV-1 vaccines. FEMS Microbiol. Lett. 200:123-129.
29. Schulick, A. H., G. Vassalli, P. F. Dunn, G. Dong, J. J. Rade, C. Zamarron, and D. A. Dichek. 1997. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J. Clin. Investig. 99:209-219.
30. Seshidhar Reddy, P., S. Ganesh, M. P. Limbach, T. Brann, A. Pinkstaff, M. Kaloss, M. Kaleko, and S. Connelly. 2003. Development of adenovirus serotype 35 as a gene transfer vector. Virology 311:384-393.
31. Toogood, C., J. Crompton, and R. Hay. 1992. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J. Gen. Virol. 73:1429-1435.
32. Tursz, T., A. Le Cesne, P. Baklerou, E. Gautier, P. Opolon, C. Schatz, A. Pavirini, M. Courtney, D. Lamy, T. Ragot, P. Saulnier, A. Andremont, R. Monier, M. Perrcaudt, and T. Le Chevalier. 1996. A study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J. Natl. Cancer Inst. 88:1857-1863.
33. Vogels, R., D. Zuijdgeest, R. van Rijnsoever, E. Hartkoorn, I. Damen, M. P. de Bethune, S. Kostense, G. Penders, N. Helmus, W. Koudstaal, M. Cecchini, A. Wetterwald, M. Sprangers, A. Lemckert, O. Ophorst, B. Koel, M. van Meerendonk, P. Quax, L. Panitti, J. Grimbergen, A. Bout, J. Goudsmit, and M. Havenga. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of pre-existing adenovirus immunity J. Virol. 77:8263-8271.
34. Wadell, G., A. Allard, and J. C. Hierholzer. 1999. Adenovirus, p. 970-982. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
35. Walters, R. W., T. Grunst, J. M. Bergelson, R. W. Finberg, M. J. Welsh, and J. Zabner. 1999. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J. Biol. Chem. 274:10219-10226.
36. Yang, Y., G. Trinchieri, and J. M. Wilmson. 1995. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med. 1:890-893.
37. Yang, Y., Q. Li, H. C. Ertl, and J. M. Wilson. 1995. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses J. Virol. 69:2004-2015.